Showing 1041-1050 of 1092 results for "".
- TempSure Vitalia from Cynosure Hits North American Markethttps://modernaesthetics.com/news/tempsure-vitalia-from-cynosure-hits-north-american-market/2472068/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to inter
- Modern Aesthetics® Announces New Tweet Chat Series -- #RealDealAestheticshttps://modernaesthetics.com/news/modern-aesthetics-announces-new-tweet-chat-series-realdealaesthetics/2472073/Modern Aesthetics® magazine is launching a new Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The first Tweet chat focuses on filler selection in a r
- First-ever Data on Vaginal Regeneration for ThermiVahttps://modernaesthetics.com/news/first-ever-data-on-vaginal-regeneration-for-thermiva/2472081/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used in more t
- Revance Vet Tapped as New Evolus CFOhttps://modernaesthetics.com/news/revance-vet-tapped-as-new-evolus-cfo/2472086/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Carrie Strom is Allergan's New Senior Vice President, U.S. Medical Aestheticshttps://modernaesthetics.com/news/carrie-strom-is-allergans-new-senior-vice-president-us-medical-aesthetics/2472094/Carrie Strom is Allergan’s new Senior Vice President, U.S. Medical Aesthetics, a portfolio of brands including BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® Collection of Fillers, Natrelle® col
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- New Merz Survey Highlights Misconceptions about Tattoo Removalhttps://modernaesthetics.com/news/new-merz-survey-highlights-misconceptions-about-tattoo-removal/2472104/More than four in five adults with (86 percent) and without (82 percent) tattoos have misconceptions about tattoo removal, including confusion regarding side effects, cost and removability, according to a new Merz survey. In addition to not knowing how the process works, many underestimat
- New AAFPRS Data: Social Media Makes Lasting Impact on Industryhttps://modernaesthetics.com/news/new-aafprs-data-social-media-makes-lasting-impact-on-industry/2472141/Like it or not, the selfie and its impact on aesthetics is here to stay, and continues to have a huge effect on how we perceive and project ourselves in front of the camera and off. This is among the main findings from the annual survey of the
- New From Cutera: Juliet and Secret RFhttps://modernaesthetics.com/news/new-from-cutera-juliet-and-secret-rf/2472149/Cutera has introduced two new devices to its laser and energy-based device offerings: Juliet™ and Secret RF
- Investigational Neurotoxin Achieves 6-Month Duration in Phase 3: Revancehttps://modernaesthetics.com/news/investigational-neurotoxin-achieves-6-month-duration-in-phase-3-revance/2472157/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared generally safe an